Kevin D. Freeman Acquires 5,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Kevin D. Freeman purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was acquired at an average cost of $2.70 per share, for a total transaction of $13,500.00. Following the transaction, the director now owns 33,469 shares in the company, valued at $90,366.30. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Galectin Therapeutics Stock Performance

NASDAQ:GALT opened at $2.66 on Friday. Galectin Therapeutics Inc. has a 52 week low of $1.55 and a 52 week high of $4.27. The firm has a 50-day moving average price of $2.57 and a two-hundred day moving average price of $2.73. The firm has a market cap of $165.31 million, a price-to-earnings ratio of -3.59 and a beta of 0.61.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). As a group, sell-side analysts forecast that Galectin Therapeutics Inc. will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Galectin Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Sanctuary Advisors LLC purchased a new stake in Galectin Therapeutics during the second quarter worth about $227,000. Squarepoint Ops LLC increased its stake in shares of Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after purchasing an additional 36,139 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Galectin Therapeutics in the 2nd quarter worth approximately $43,000. Rhumbline Advisers bought a new stake in shares of Galectin Therapeutics in the 2nd quarter worth approximately $44,000. Finally, Commonwealth Equity Services LLC lifted its stake in Galectin Therapeutics by 317.6% in the second quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock valued at $1,092,000 after purchasing an additional 367,610 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GALT. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a report on Friday, August 16th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.